title: CD99 engagement: an effective therapeutic strategy for Ewing tumors.
abstract: CD99 is a Mr 32,000 transmembrane molecule that shows a high level of expression on cells of the hemopoietic system as well as on Ewing tumor cells. Within the hematopoietic system, CD99 has been implicated in cell adhesion and cell death, participating in this way in the differentiation of T-cell precursors. In this study, we demonstrate that engagement of CD99 significantly inhibits the in vitro and in vivo growth ability of Ewing tumor cells by delivering an apoptotic stimulus and reducing the malignant potential of these cells. Moreover, we show that anti-CD99 monoclonal antibodies may be advantageously used in association with conventional anticancer agents. These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement.
authors.affiliation: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy. katia.scotlandi@ior.it
authors.forename: K
authors.initials: K
authors.lastname: Scotlandi
authors.forename: N
authors.initials: N
authors.lastname: Baldini
authors.forename: V
authors.initials: V
authors.lastname: Cerisano
authors.forename: M C
authors.initials: MC
authors.lastname: Manara
authors.forename: S
authors.initials: S
authors.lastname: Benini
authors.forename: M
authors.initials: M
authors.lastname: Serra
authors.forename: P L
authors.initials: PL
authors.lastname: Lollini
authors.forename: P
authors.initials: P
authors.lastname: Nanni
authors.forename: G
authors.initials: G
authors.lastname: Nicoletti
authors.forename: G
authors.initials: G
authors.lastname: Bernard
authors.forename: A
authors.initials: A
authors.lastname: Bernard
authors.forename: P
authors.initials: P
authors.lastname: Picci
mesh_terms: D000071443:12E7 Antigen; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000276:immunology / Q000502:physiology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D017209:Apoptosis / Q000502:physiology; D001859:Bone Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D015815:Cell Adhesion Molecules / Q000276:immunology / Q000502:physiology*; D002449:Cell Aggregation / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D019169:Jurkat Cells; D051379:Mice; D008819:Mice, Nude; D012516:Osteosarcoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D014407:Tumor Cells, Cultured; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000071443:12E7 Antigen; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C061828:CD99 protein, human; D015815:Cell Adhesion Molecules; D014750:Vincristine; D004317:Doxorubicin